Why cure, why now?
- PMID: 27273887
- PMCID: PMC5293855
- DOI: 10.1136/medethics-2015-103113
Why cure, why now?
Abstract
Combination antiretroviral therapy (cART) is highly effective at preventing morbidity and mortality due to infection with human immunodeficiency virus (HIV), but does not eradicate the virus. Consequently, cART must be administered life-long. Recent progress has stimulated research towards a cure of HIV infection. Approaches under investigation include hematopoietic stem cell transplantation, latency reactivating agents, immune based therapies, and cell-based therapies. Each of these approaches carries potential risks that must be weighed against the availability of safe and effective cART. Balancing the risks and benefits of this research poses unique challenges to potential study participants, clinicians and investigators.
Keywords: Clinical trials; Ethics; HIV Infection and AIDS.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Conflict of interest statement
Competing interests: None declared.
References
-
- World Health Organization. HIV/AIDS Data and Statistics. http://www.who.int/hiv/data/epi_core_july2015.png?ua=1 (accessed 7 Apr 2016).
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical